{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:56:39Z","timestamp":1787313399887,"version":"build-2736575974"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,3,16]],"date-time":"2013-03-16T00:00:00Z","timestamp":1363392000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1471-2407-13-122","type":"journal-article","created":{"date-parts":[[2013,3,16]],"date-time":"2013-03-16T11:14:20Z","timestamp":1363432460000},"source":"Crossref","is-referenced-by-count":20,"title":["Time-dependent endpoints as predictors of overall survival in multiple myeloma"],"prefix":"10.1186","volume":"13","author":[{"given":"Jorge","family":"F\u00e9lix","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipa","family":"Arag\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o M","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederico JM","family":"Calado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ant\u00f3nio BS","family":"Parreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o FR","family":"Rijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,3,16]]},"reference":[{"key":"3757_CR1","volume-title":"Cancer Facts & Figures","author":"American Cancer Society","year":"2010","unstructured":"American Cancer Society: Cancer Facts & Figures. 2010, http:\/\/www.cancer.org\/acs\/groups\/content\/@nho\/documents\/document\/acspc-024113.pdf ,"},{"key":"3757_CR2","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u2122): Multiple myeloma, Version 2","author":"National Comprehensive Cancer Network","year":"2010","unstructured":"National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u2122): Multiple myeloma, Version 2. 2010, http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp ,"},{"key":"3757_CR3","volume-title":"Surveillance Epidemiology and End Results. SEER Stat Fact Sheets: Myeloma","author":"National Cancer Institute","year":"2010","unstructured":"National Cancer Institute: Surveillance Epidemiology and End Results. SEER Stat Fact Sheets: Myeloma. 2010, http:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html ,"},{"key":"3757_CR4","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/j.ejca.2006.01.065","volume":"42","author":"B Sirohi","year":"2006","unstructured":"Sirohi B, Powles R: Epidemiology and outcomes research for MGUS, myeloma and amyloidosis. Eur J Cancer. 2006, 42: 1671-1683. 10.1016\/j.ejca.2006.01.065.","journal-title":"Eur J Cancer"},{"key":"3757_CR5","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.4065\/83.10.1142","volume":"83","author":"SV Rajkumar","year":"2008","unstructured":"Rajkumar SV: Treatment of myeloma: cure vs control. Mayo Clin Proc. 2008, 83: 1142-1145. 10.4065\/83.10.1142.","journal-title":"Mayo Clin Proc"},{"key":"3757_CR6","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s10147-009-0885-4","volume":"14","author":"Q Shi","year":"2009","unstructured":"Shi Q, Sargent DJ: Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials. Int J Clin Oncol. 2009, 14: 102-111. 10.1007\/s10147-009-0885-4.","journal-title":"Int J Clin Oncol"},{"key":"3757_CR7","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1200\/JCO.2008.20.4107","volume":"27","author":"TR Fleming","year":"2009","unstructured":"Fleming TR, Rothmann MD, Lu HL: Issues in using progression-free survival when evaluating oncology products. J Clin Oncol. 2009, 27: 2874-2880. 10.1200\/JCO.2008.20.4107.","journal-title":"J Clin Oncol"},{"key":"3757_CR8","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1200\/JCO.2011.34.6056","volume":"29","author":"EL Korn","year":"2011","unstructured":"Korn EL, Freidlin B, Abrams JS: Overall survival as the outcome for randomized clinical trials with effective subsequent therapies. J Clin Oncol. 2011, 29: 2439-2442. 10.1200\/JCO.2011.34.6056.","journal-title":"J Clin Oncol"},{"key":"3757_CR9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1097\/PPO.0b013e3181be231d","volume":"15","author":"SH Zhuang","year":"2009","unstructured":"Zhuang SH, Xiu L, Elsayed YA: Overall survival: a gold standard in search of a surrogate: the value of progression-free survival and time to progression as end points of drug efficacy. Cancer J. 2009, 15: 395-400. 10.1097\/PPO.0b013e3181be231d.","journal-title":"Cancer J"},{"key":"3757_CR10","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.ejca.2005.03.002","volume":"41","author":"R Cooper","year":"2005","unstructured":"Cooper R, Kaanders JH: Biological surrogate end-points in cancer trials: potential uses, benefits and pitfalls. Eur J Cancer. 2005, 41: 1261-1266. 10.1016\/j.ejca.2005.03.002.","journal-title":"Eur J Cancer"},{"key":"3757_CR11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nrclinonc.2010.43","volume":"7","author":"M Buyse","year":"2010","unstructured":"Buyse M, Sargent DJ, Grothey A: Biomarkers and surrogate end points\u2013the challenge of statistical validation. Nat Rev Clin Oncol. 2010, 7: 309-317. 10.1038\/nrclinonc.2010.43.","journal-title":"Nat Rev Clin Oncol"},{"key":"3757_CR12","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1093\/jnci\/djj153","volume":"98","author":"SG Baker","year":"2006","unstructured":"Baker SG: Surrogate endpoints: wishful thinking or reality?. J Natl Cancer Inst. 2006, 98: 502-503. 10.1093\/jnci\/djj153.","journal-title":"J Natl Cancer Inst"},{"key":"3757_CR13","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/jnci\/djp399","volume":"101","author":"R Tuma","year":"2009","unstructured":"Tuma R: Progression-free survival remains debatable endpoint in cancer trials. J Natl Cancer Inst. 2009, 101: 1439-1441. 10.1093\/jnci\/djp399.","journal-title":"J Natl Cancer Inst"},{"key":"3757_CR14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1017\/S0266462309090023","volume":"25","author":"J Elston","year":"2009","unstructured":"Elston J, Taylor RS: Use of surrogate outcomes in cost-effectiveness models: a review of United Kingdom health technology assessment reports. Int J Technol Assess Health Care. 2009, 25: 6-13. 10.1017\/S0266462309090023.","journal-title":"Int J Technol Assess Health Care"},{"key":"3757_CR15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1017\/S0266462309990213","volume":"25","author":"M Velasco Garrido","year":"2009","unstructured":"Velasco Garrido M, Mangiapane S: Surrogate outcomes in health technology assessment: an international comparison. Int J Technol Assess Health Care. 2009, 25: 315-322. 10.1017\/S0266462309990213.","journal-title":"Int J Technol Assess Health Care"},{"key":"3757_CR16","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1200\/JCO.2003.08.072","volume":"21","author":"JR Johnson","year":"2003","unstructured":"Johnson JR, Williams G, Pazdur R: End points and United States food and drug administration approval of oncology drugs. J Clin Oncol. 2003, 21: 1404-1411. 10.1200\/JCO.2003.08.072.","journal-title":"J Clin Oncol"},{"key":"3757_CR17","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/sj.leu.2405016","volume":"22","author":"KC Anderson","year":"2008","unstructured":"Anderson KC, Kyle RA, Rajkumar SV: Clinically relevant end points and new drug approvals for myeloma. Leukemia. 2008, 22: 231-239. 10.1038\/sj.leu.2405016.","journal-title":"Leukemia"},{"key":"3757_CR18","volume-title":"Econometric analysis","author":"WH Greene","year":"2003","unstructured":"Greene WH: Econometric analysis. 2003, New Jersey: Prentice Hall, 5","edition":"5"},{"key":"3757_CR19","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.2307\/1912775","volume":"50","author":"LP Hansen","year":"1982","unstructured":"Hansen LP: Large sample properties of generalized method of moments estimators. Econometrica. 1982, 50: 1029-1054. 10.2307\/1912775.","journal-title":"Econometrica"},{"key":"3757_CR20","first-page":"221","volume-title":"Fifth Berkeley Symposium on Mathematical Statistics and Probability. Volume 1","author":"PJ Huber","year":"1967","unstructured":"Huber PJ: The behavior of maximum likelihood estimates under nonstandard conditions. Fifth Berkeley Symposium on Mathematical Statistics and Probability. Volume 1. Edited by: Le Cam LM, Neyman J. 1967, Berkeley, CA: University of California Press, 221-233."},{"key":"3757_CR21","doi-asserted-by":"publisher","first-page":"817","DOI":"10.2307\/1912934","volume":"48","author":"H White","year":"1980","unstructured":"White H: A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity. Econometrica. 1980, 48: 817-830. 10.2307\/1912934.","journal-title":"Econometrica"},{"key":"3757_CR22","doi-asserted-by":"publisher","first-page":"679","DOI":"10.2307\/1911314","volume":"54","author":"RJ Smith","year":"1986","unstructured":"Smith RJ, Blundell RW: An exogeneity test for a simultaneous equation Tobit model with an application to labor supply. Econometrica. 1986, 54: 679-685. 10.2307\/1911314.","journal-title":"Econometrica"},{"key":"3757_CR23","doi-asserted-by":"publisher","first-page":"751","DOI":"10.2307\/1912156","volume":"51","author":"JG Cragg","year":"1983","unstructured":"Cragg JG: More efficient estimation in the presence of heteroskedasticity of unknown form. Econometrica. 1983, 51: 751-763. 10.2307\/1912156.","journal-title":"Econometrica"},{"key":"3757_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2307\/1401917","volume":"22","author":"J Durbin","year":"1954","unstructured":"Durbin J: Errors in variables. Rev Int Stat Inst. 1954, 22: 23-32. 10.2307\/1401917.","journal-title":"Rev Int Stat Inst"},{"key":"3757_CR25","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.2307\/1913827","volume":"46","author":"J Hausman","year":"1978","unstructured":"Hausman J: Specification tests in econometrics. Econometrica. 1978, 46: 1251-1271. 10.2307\/1913827.","journal-title":"Econometrica"},{"key":"3757_CR26","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2307\/1914093","volume":"41","author":"DM Wu","year":"1973","unstructured":"Wu DM: Alternative tests of independence between stochastic regressors and disturbances. Econometrica. 1973, 41: 733-750. 10.2307\/1914093.","journal-title":"Econometrica"},{"issue":"2","key":"3757_CR27","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jeconom.2012.05.008","volume":"170","author":"L Hansen","year":"2012","unstructured":"Hansen L: Proofs for large sample properties of generalized method of moments estimators. J Econ. 2012, 170 (2): 325-330.","journal-title":"J Econ"},{"key":"3757_CR28","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.2307\/1911963","volume":"47","author":"TS Breusch","year":"1979","unstructured":"Breusch TS, Pagan AR: A simple test for heteroskedasticity and random coefficient variation. Econometrica. 1979, 47: 1287-1294. 10.2307\/1911963.","journal-title":"Econometrica"},{"key":"3757_CR29","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.2517-6161.1969.tb00796.x","volume":"31","author":"JB Ramsey","year":"1969","unstructured":"Ramsey JB: Tests for specification errors in classical linear least squares regression analysis. J Roy Stat Soc B. 1969, 31: 350-371.","journal-title":"J Roy Stat Soc B"},{"key":"3757_CR30","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1038\/sj.bjc.6604759","volume":"99","author":"B Sherrill","year":"2008","unstructured":"Sherrill B, Amonkar M, Wu Y: Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer. Br J Cancer. 2008, 99: 1572-1578. 10.1038\/sj.bjc.6604759.","journal-title":"Br J Cancer"},{"key":"3757_CR31","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1200\/JCO.2006.08.1935","volume":"25","author":"PA Tang","year":"2007","unstructured":"Tang PA, Bentzen SM, Chen EX: Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol. 2007, 25: 4562-4568. 10.1200\/JCO.2006.08.1935.","journal-title":"J Clin Oncol"},{"key":"3757_CR32","doi-asserted-by":"crossref","DOI":"10.1002\/9781119013563","volume-title":"Statistical Analysis with Missing Data","author":"R Little","year":"2002","unstructured":"Little R, Rubin D: Statistical Analysis with Missing Data. 2002, New York: John Wiley and Sons, 2","edition":"2"},{"key":"3757_CR33","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s11899-011-0080-3","volume":"6","author":"MV Mateos","year":"2011","unstructured":"Mateos MV, San-Miguel J: Treatment of newly diagnosed myeloma in patients not eligible for transplantation. Curr Hematol Malig Rep. 2011, 6: 113-119. 10.1007\/s11899-011-0080-3.","journal-title":"Curr Hematol Malig Rep"},{"key":"3757_CR34","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1634\/theoncologist.2009-0203","volume":"15","author":"H Ludwig","year":"2010","unstructured":"Ludwig H, Beksac M, Blade J: Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist. 2010, 15: 6-25. 10.1634\/theoncologist.2009-0203.","journal-title":"Oncologist"},{"key":"3757_CR35","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1182\/asheducation-2011.1.197","volume":"2011","author":"DE Reece","year":"2011","unstructured":"Reece DE: Posttransplantation maintenance therapy and optimal frontline therapy in myeloma. Hematology Am Soc Hematol Educ Program. 2011, 2011: 197-204. 10.1182\/asheducation-2011.1.197.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"3757_CR36","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1182\/blood-2008-07-169565","volume":"113","author":"H Ludwig","year":"2009","unstructured":"Ludwig H, Hajek R, Tothova E: Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood. 2009, 113: 3435-3442. 10.1182\/blood-2008-07-169565.","journal-title":"Blood"},{"key":"3757_CR37","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1182\/blood-2011-02-338665","volume":"118","author":"GJ Morgan","year":"2011","unstructured":"Morgan GJ, Davies FE, Gregory WM: Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood. 2011, 118: 1231-1238. 10.1182\/blood-2011-02-338665.","journal-title":"Blood"},{"key":"3757_CR38","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1200\/JCO.2009.26.1610","volume":"28","author":"P Wijermans","year":"2010","unstructured":"Wijermans P, Schaafsma M, Termorshuizen F: Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 study. J Clin Oncol. 2010, 28: 3160-3166. 10.1200\/JCO.2009.26.1610.","journal-title":"J Clin Oncol"},{"key":"3757_CR39","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1182\/blood-2009-08-237974","volume":"116","author":"A Waage","year":"2010","unstructured":"Waage A, Gimsing P, Fayers P: Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood. 2010, 116: 1405-1412. 10.1182\/blood-2009-08-237974.","journal-title":"Blood"},{"key":"3757_CR40","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1600-0609.2010.01524.x","volume":"86","author":"M Beksac","year":"2010","unstructured":"Beksac M, Haznedar R, Firatli-Tuglular T: Addition of thalidomide to oral melphalan\/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish myeloma study group. Eur J Haematol. 2010, 86: 16-22.","journal-title":"Eur J Haematol"},{"key":"3757_CR41","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1182\/blood-2008-04-149427","volume":"112","author":"A Palumbo","year":"2008","unstructured":"Palumbo A, Bringhen S, Liberati AM: Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood. 2008, 112: 3107-3114. 10.1182\/blood-2008-04-149427.","journal-title":"Blood"},{"key":"3757_CR42","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","volume":"370","author":"T Facon","year":"2007","unstructured":"Facon T, Mary JY, Hulin C: Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99\u201306): a randomised trial. Lancet. 2007, 370: 1209-1218. 10.1016\/S0140-6736(07)61537-2.","journal-title":"Lancet"},{"key":"3757_CR43","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","volume":"27","author":"C Hulin","year":"2009","unstructured":"Hulin C, Facon T, Rodon P: Efficacy of melphalan and prednisone plus thalidomide in patients older than 75\u00a0years with newly diagnosed multiple myeloma: IFM 01\/01 trial. J Clin Oncol. 2009, 27: 3664-3670. 10.1200\/JCO.2008.21.0948.","journal-title":"J Clin Oncol"},{"key":"3757_CR44","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"JF San Miguel","year":"2008","unstructured":"San Miguel JF, Schlag R, Khuageva NK: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008, 359: 906-917. 10.1056\/NEJMoa0801479.","journal-title":"N Engl J Med"},{"key":"3757_CR45","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.V116.21.619.619","volume":"116","author":"R Niesvizky","year":"2010","unstructured":"Niesvizky R, Flinn IW, Rifkin RM: Phase 3b UPFRONT Study: safety and efficacy of weekly bortezomib maintenance therapy after bortezomib-based induction regimens in elderly, newly diagnosed multiple myeloma patients [abstract]. Blood. 2010, 116: 619-","journal-title":"Blood"},{"key":"3757_CR46","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","volume":"11","author":"MV Mateos","year":"2010","unstructured":"Mateos MV, Oriol A, Martinez-Lopez J: Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 2010, 11: 934-941. 10.1016\/S1470-2045(10)70187-X.","journal-title":"Lancet Oncol"},{"key":"3757_CR47","doi-asserted-by":"publisher","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","volume":"28","author":"A Palumbo","year":"2010","unstructured":"Palumbo A, Bringhen S, Rossi D: Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol. 2010, 28: 5101-5109. 10.1200\/JCO.2010.29.8216.","journal-title":"J Clin Oncol"},{"key":"3757_CR48","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1182\/blood-2010-05-285155","volume":"116","author":"A Palumbo","year":"2010","unstructured":"Palumbo A, Delforge M, Catalano J: A phase 3 study evaluating the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients \u226565\u00a0years with newly diagnosed multiple myeloma (NDMM): continuous use of lenalidomide vs fixed-duration regimens [abstract]. Blood. 2010, 116: 622-","journal-title":"Blood"},{"key":"3757_CR49","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","volume":"11","author":"SV Rajkumar","year":"2010","unstructured":"Rajkumar SV, Jacobus S, Callander NS: Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010, 11: 29-37. 10.1016\/S1470-2045(09)70284-0.","journal-title":"Lancet Oncol"},{"key":"3757_CR50","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1038\/leu.2009.147","volume":"23","author":"MA Dimopoulos","year":"2009","unstructured":"Dimopoulos MA, Chen C, Spencer A: Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009, 23: 2147-2152. 10.1038\/leu.2009.147.","journal-title":"Leukemia"},{"key":"3757_CR51","doi-asserted-by":"publisher","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","volume":"110","author":"PG Richardson","year":"2007","unstructured":"Richardson PG, Sonneveld P, Schuster M: Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007, 110: 3557-3560. 10.1182\/blood-2006-08-036947.","journal-title":"Blood"},{"key":"3757_CR52","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","volume":"25","author":"RZ Orlowski","year":"2007","unstructured":"Orlowski RZ, Nagler A, Sonneveld P: Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007, 25: 3892-3901. 10.1200\/JCO.2006.10.5460.","journal-title":"J Clin Oncol"},{"key":"3757_CR53","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1182\/blood-2010-04-281212","volume":"116","author":"AK Stewart","year":"2010","unstructured":"Stewart AK, Trudel S, Bahlis NJ: A randomized phase III trial of thalidomide and prednisone as maintenance therapy following autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM): the NCIC CTG MY.10 trial [abstract]. Blood. 2010, 116: 39-","journal-title":"Blood"},{"key":"3757_CR54","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1200\/JCO.2008.18.8573","volume":"27","author":"A Spencer","year":"2009","unstructured":"Spencer A, Prince HM, Roberts AW: Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol. 2009, 27: 1788-1793. 10.1200\/JCO.2008.18.8573.","journal-title":"J Clin Oncol"},{"key":"3757_CR55","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2011-06-357038","volume":"119","author":"GJ Morgan","year":"2012","unstructured":"Morgan GJ, Gregory WM, Davies FE: The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood. 2012, 119: 7-15. 10.1182\/blood-2011-06-357038.","journal-title":"Blood"},{"key":"3757_CR56","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1182\/blood-2009-05-222539","volume":"115","author":"HM Lokhorst","year":"2009","unstructured":"Lokhorst HM, van der Holt B, Zweegman S: A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood. 2009, 115: 1113-1120.","journal-title":"Blood"},{"key":"3757_CR57","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood.V116.21.40.40","volume":"116","author":"P Sonneveld","year":"2010","unstructured":"Sonneveld P, Schmidt-Wolf I, van der Holt B: HOVON-65\/GMMG-HD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM) [abstract]. Blood. 2010, 116: 40-","journal-title":"Blood"},{"key":"3757_CR58","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.3324\/haematol.2011.041319","volume":"96","author":"P McCarthy","year":"2011","unstructured":"McCarthy P, Owzar K, Anderson K: Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB ECOG BMT-CTN 100104 [abstract]. Haematologica. 2011, 96: S23-10.3324\/haematol.2011.041319.","journal-title":"Haematologica"},{"key":"3757_CR59","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.3324\/haematol.2011.041319","volume":"96","author":"M Attal","year":"2011","unstructured":"Attal M, Olivier P, Cances-Lauwers V: Maintenance treatment with lenalidomide after transplantation for myeloma: analysis of secondary malignancies within the IFM 2005\u201302 trial. Haematologica. 2011, 96: S23-10.3324\/haematol.2011.041319.","journal-title":"Haematologica"},{"key":"3757_CR60","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1183\/09031936.00190310","volume":"39","author":"T Berghmans","year":"2012","unstructured":"Berghmans T, Pasleau F, Paesmans M: Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations. Eur Respir J. 2012, 39: 9-28. 10.1183\/09031936.00190310.","journal-title":"Eur Respir J"},{"key":"3757_CR61","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1097\/PPO.0b013e3181b9c602","volume":"15","author":"M Buyse","year":"2009","unstructured":"Buyse M: Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials. Cancer J. 2009, 15: 421-425. 10.1097\/PPO.0b013e3181b9c602.","journal-title":"Cancer J"},{"key":"3757_CR62","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.1200\/JCO.2007.11.8836","volume":"25","author":"M Buyse","year":"2007","unstructured":"Buyse M, Burzykowski T, Carroll K: Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol. 2007, 25: 5218-5224. 10.1200\/JCO.2007.11.8836.","journal-title":"J Clin Oncol"},{"key":"3757_CR63","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.3324\/haematol.2010.039131","volume":"96","author":"M Buyse","year":"2011","unstructured":"Buyse M, Michiels S, Squifflet P: Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission. Haematologica. 2011, 96: 1106-1112. 10.3324\/haematol.2010.039131.","journal-title":"Haematologica"},{"key":"3757_CR64","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/sj.bjc.6602858","volume":"93","author":"A Hackshaw","year":"2005","unstructured":"Hackshaw A, Knight A, Barrett-Lee P: Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer. Br J Cancer. 2005, 93: 1215-1221. 10.1038\/sj.bjc.6602858.","journal-title":"Br J Cancer"},{"key":"3757_CR65","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/JTO.0b013e3181989bd2","volume":"4","author":"K Hotta","year":"2009","unstructured":"Hotta K, Fujiwara Y, Matsuo K: Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2009, 4: 311-317. 10.1097\/JTO.0b013e3181989bd2.","journal-title":"J Thorac Oncol"},{"key":"3757_CR66","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S1470-2045(06)70800-2","volume":"7","author":"KR Johnson","year":"2006","unstructured":"Johnson KR, Ringland C, Stokes BJ: Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol. 2006, 7: 741-746. 10.1016\/S1470-2045(06)70800-2.","journal-title":"Lancet Oncol"},{"key":"3757_CR67","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1093\/annonc\/mdq615","volume":"22","author":"L Lee","year":"2011","unstructured":"Lee L, Wang L, Crump M: Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin\u2019s lymphoma: correlation of complete response, time-to-event and overall survival end points. Ann Oncol. 2011, 22: 1392-1403. 10.1093\/annonc\/mdq615.","journal-title":"Ann Oncol"},{"key":"3757_CR68","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S1470-2045(09)70023-3","volume":"10","author":"S Michiels","year":"2009","unstructured":"Michiels S, Le Maitre A, Buyse M: Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. Lancet Oncol. 2009, 10: 341-350. 10.1016\/S1470-2045(09)70023-3.","journal-title":"Lancet Oncol"},{"key":"3757_CR69","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1017\/S0266462308080495","volume":"24","author":"RA Miksad","year":"2008","unstructured":"Miksad RA, Zietemann V, Gothe R: Progression-free survival as a surrogate endpoint in advanced breast cancer. Int J Technol Assess Health Care. 2008, 24: 371-383.","journal-title":"Int J Technol Assess Health Care"},{"key":"3757_CR70","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1200\/JCO.2006.10.4323","volume":"25","author":"DJ Sargent","year":"2007","unstructured":"Sargent DJ, Patiyil S, Yothers G: End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol. 2007, 25: 4569-4574. 10.1200\/JCO.2006.10.4323.","journal-title":"J Clin Oncol"},{"key":"3757_CR71","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1007\/s10637-011-9648-y","volume":"30","author":"K Shitara","year":"2012","unstructured":"Shitara K, Ikeda J, Yokota T: Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials. Invest New Drugs. 2012, 30: 1224-1231. 10.1007\/s10637-011-9648-y.","journal-title":"Invest New Drugs"},{"key":"3757_CR72","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1200\/JCO.2007.10.8407","volume":"26","author":"T Burzykowski","year":"2008","unstructured":"Burzykowski T, Buyse M, Piccart-Gebhart MJ: Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol. 2008, 26: 1987-1992. 10.1200\/JCO.2007.10.8407.","journal-title":"J Clin Oncol"},{"key":"3757_CR73","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s10147-011-0231-5","volume":"16","author":"Y Matsubara","year":"2011","unstructured":"Matsubara Y, Sakabayashi S, Nishimura T: Surrogacy of tumor response and progression-free survival for overall survival in metastatic breast cancer resistant to both anthracyclines and taxanes. Int J Clin Oncol. 2011, 16: 623-629. 10.1007\/s10147-011-0231-5.","journal-title":"Int J Clin Oncol"},{"key":"3757_CR74","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1177\/0962280207081862","volume":"17","author":"A Chakravarty","year":"2008","unstructured":"Chakravarty A, Sridhara R: Use of progression-free survival as a surrogate marker in oncology trials: some regulatory issues. Stat Methods Med Res. 2008, 17: 515-518. 10.1177\/0962280207081862.","journal-title":"Stat Methods Med Res"},{"key":"3757_CR75","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/jnci\/djn515","volume":"101","author":"RL Prentice","year":"2009","unstructured":"Prentice RL: Surrogate and mediating endpoints: current status and future directions. J Natl Cancer Inst. 2009, 101: 216-217. 10.1093\/jnci\/djn515.","journal-title":"J Natl Cancer Inst"},{"key":"3757_CR76","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1182\/blood-2011-06-297853","volume":"118","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Gahrton G, Bergsagel PL: Approach to the treatment of multiple myeloma: a clash of philosophies. Blood. 2011, 118: 3205-3211. 10.1182\/blood-2011-06-297853.","journal-title":"Blood"},{"issue":"Suppl 2","key":"3757_CR77","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.3390\/curroncol18120004","volume":"18","author":"JA Maroun","year":"2011","unstructured":"Maroun JA: The significance of progression-free survival as an endpoint in evaluating the therapeutic value of antineoplastic agents. Curr Oncol. 2011, 18 (Suppl 2): S3-S4.","journal-title":"Curr Oncol"},{"key":"3757_CR78","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1634\/theoncologist.2010-0278","volume":"16","author":"S Verma","year":"2011","unstructured":"Verma S, McLeod D, Batist G: In the end what matters most? A review of clinical endpoints in advanced breast cancer. Oncologist. 2011, 16: 25-35.","journal-title":"Oncologist"},{"key":"3757_CR79","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/annonc\/mdp523","volume":"21","author":"ED Saad","year":"2010","unstructured":"Saad ED, Katz A, Hoff PM: Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Ann Oncol. 2010, 21: 7-12. 10.1093\/annonc\/mdp523.","journal-title":"Ann Oncol"},{"key":"3757_CR80","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/pst.406","volume":"10","author":"SW Duffy","year":"2011","unstructured":"Duffy SW, Treasure FP: Potential surrogate endpoints in cancer research\u2013some considerations and examples. Pharm Stat. 2011, 10: 34-39. 10.1002\/pst.406.","journal-title":"Pharm Stat"},{"key":"3757_CR81","volume-title":"The clinical and cost-effectiveness of lenalidomide for multiple myeloma in people who have received at least one prior therapy: An evidence review of the submission from Celgene","author":"Peninsula Technology Assessment Group","year":"2008","unstructured":"Peninsula Technology Assessment Group: The clinical and cost-effectiveness of lenalidomide for multiple myeloma in people who have received at least one prior therapy: An evidence review of the submission from Celgene. 2008, http:\/\/www.hta.ac.uk\/erg\/reports\/1746.pdf ,"},{"key":"3757_CR82","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005, 352: 2487-2498. 10.1056\/NEJMoa043445.","journal-title":"N Engl J Med"},{"key":"3757_CR83","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.1200\/JCO.2007.11.8711","volume":"25","author":"B Freidlin","year":"2007","unstructured":"Freidlin B, Korn EL, George SL: Randomized clinical trial design for assessing noninferiority when superiority is expected. J Clin Oncol. 2007, 25: 5019-5023. 10.1200\/JCO.2007.11.8711.","journal-title":"J Clin Oncol"},{"key":"3757_CR84","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1200\/JCO.2003.99.089","volume":"21","author":"A Di Leo","year":"2003","unstructured":"Di Leo A, Bleiberg H, Buyse M: Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer. J Clin Oncol. 2003, 21: 2045-2047. 10.1200\/JCO.2003.99.078.","journal-title":"J Clin Oncol"},{"key":"3757_CR85","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A: Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008, 111: 2516-2520. 10.1182\/blood-2007-10-116129.","journal-title":"Blood"},{"key":"3757_CR86","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1200\/JCO.2010.31.6455","volume":"29","author":"M Colleoni","year":"2011","unstructured":"Colleoni M, Giobbie-Hurder A, Regan MM: Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1\u201398 study. J Clin Oncol. 2011, 29: 1117-1124. 10.1200\/JCO.2010.31.6455.","journal-title":"J Clin Oncol"},{"key":"3757_CR87","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1471-2288-11-4","volume":"11","author":"JP Morden","year":"2011","unstructured":"Morden JP, Lambert PC, Latimer N: Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study. BMC Med Res Methodol. 2011, 11: 4-10.1186\/1471-2288-11-4.","journal-title":"BMC Med Res Methodol"},{"key":"3757_CR88","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jval.2011.02.1182","volume":"14","author":"KJ Ishak","year":"2011","unstructured":"Ishak KJ, Caro JJ, Drayson MT: Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma. Value Health. 2011, 14: 672-678. 10.1016\/j.jval.2011.02.1182.","journal-title":"Value Health"},{"key":"3757_CR89","doi-asserted-by":"publisher","first-page":"A437","DOI":"10.1016\/j.jval.2011.08.1124","volume":"14","author":"M Pacou","year":"2011","unstructured":"Pacou M, Gauthier A, Abrams K: Survival analysis adjusted for crossover in relapsed multiple myeloma: Results of the APEX trial [abstract]. Value Health. 2011, 14: A437-A438.","journal-title":"Value Health"},{"key":"3757_CR90","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.critrevonc.2005.11.003","volume":"59","author":"P Therasse","year":"2006","unstructured":"Therasse P, Carbonnelle S, Bogaerts J: Clinical trials design and treatment tailoring: general principles applied to breast cancer research. Crit Rev Oncol Hematol. 2006, 59: 98-105. 10.1016\/j.critrevonc.2005.11.003.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3757_CR91","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/jnci\/djr104","volume":"103","author":"SS Ellenberg","year":"2011","unstructured":"Ellenberg SS: Accelerated approval of oncology drugs: can we do better?. J Natl Cancer Inst. 2011, 103: 616-617. 10.1093\/jnci\/djr104.","journal-title":"J Natl Cancer Inst"},{"key":"3757_CR92","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1002\/sim.2712","volume":"26","author":"H Putter","year":"2007","unstructured":"Putter H, Fiocco M, Geskus RB: Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007, 26: 2389-2430. 10.1002\/sim.2712.","journal-title":"Stat Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-122.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-13-122\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T11:07:43Z","timestamp":1715080063000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-13-122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,16]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["3757"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-13-122","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,16]]},"article-number":"122"}}